# CHR. HANSEN HOLDING A/S > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/chrhansenholding). ## Overview CHR. HANSEN HOLDING A/S is a Danish bioscience company focused on microbial and enzyme solutions used in food production, nutrition, and health applications. Its business centers on cultures, probiotics, and enzymes sold to industrial customers worldwide through a global group structure headquartered in Denmark. ## Products & services • Food cultures for dairy and other fermented foods • Enzymes for food and beverage processing • Probiotic ingredients for human health • Microbial solutions for agriculture and feed • Starter cultures and protective cultures - **Food Cultures & Enzymes** (55%) — Cultures, starter systems, and enzymes used in food processing and fermentation. - **Health & Nutrition** (30%) — Probiotic ingredients and microbial solutions for human health applications. - **Agriculture & Feed** (15%) — Microbial products used in animal nutrition, feed efficiency, and agricultural applications. - Food cultures for dairy and fermented foods - Enzymes for food and beverage processing - Probiotic ingredients for human health - Microbial solutions for agriculture and feed - Starter and protective cultures ## Customers The company sells mainly to industrial food producers, ingredient formulators, and nutrition companies that incorporate microbial solutions into finished products. Its end markets include dairy, fermented foods, dietary supplements, and agricultural/feed applications, where customers value product consistency, functionality, and application support. Demand is driven by processing needs, formulation performance, and regulatory acceptance in end-use markets. - **Dairy and fermented food producers** (primary) — Buy starter cultures and enzymes to make yogurt, cheese, and other fermented products. - **Health and nutrition companies** (primary) — Buy probiotic ingredients for supplements and functional nutrition products. - **Food ingredient processors** (secondary) — Buy cultures and enzymes to improve yield, texture, flavor, and shelf life. - **Feed and agriculture customers** (secondary) — Buy microbial solutions used in animal nutrition and farm productivity. - Dairy and fermented food manufacturers - Food ingredient and process companies - Probiotic and dietary supplement brands - Feed and animal nutrition customers - Agriculture and microbial solution users ## Geography Chr. Hansen serves customers across Europe, the Americas, and Asia through a global sales and application network. The business is internationally diversified, with demand tied to food, health, and agricultural markets in multiple regions, while manufacturing and technical support are organized globally to serve local customer requirements. - Global sales footprint across Europe, the Americas, and Asia - Customer demand is diversified across food, health, and feed markets - Local technical support matters because formulations are application-specific - Geographic spread reduces dependence on any single end market - Global supply chain exposure affects production and logistics ## Strategy The company’s strategy is built around expanding microbial and enzyme applications, supported by innovation, application support, and long customer relationships. It also emphasizes scaling in adjacent markets such as health and agricultural microbiology, where its strain libraries and fermentation expertise can be reused across products. - **Expand application breadth** (medium-term) — Broader use cases increase the addressable market for its microbial platform. - **Strengthen innovation pipeline** (medium-term) — New strains and formulations help defend pricing and create differentiated products. - **Scale adjacencies** (medium-term) — Adjacent categories reuse existing know-how and customer relationships. - Expand microbial and enzyme applications across end markets - Use strain and fermentation expertise as a competitive moat - Grow in health and nutrition adjacencies - Support customers with application-specific technical service - Invest in global manufacturing and supply capabilities ## Risks The business is exposed to customer concentration in industrial food and nutrition markets, where product qualification cycles can be long and switching costs can still be meaningful. It also faces commodity, supply-chain, and geopolitical pressure because microbial products rely on global manufacturing, transport, and raw-material availability. Scientific, regulatory, and intellectual-property risks are important because product performance and approval standards directly affect commercialization. - **Supply-chain disruption** [high] — The company relies on global production, logistics, and cold-chain or controlled handling for some products. - **Regulatory and food-safety compliance** [high] — Cultures, probiotics, and feed applications must meet local regulatory standards before use. - **Customer adoption and qualification risk** [medium] — Industrial customers often test microbial solutions extensively before switching suppliers. - **Intellectual property and strain protection** [medium] — Performance differentiation depends on proprietary strains and know-how. - Customer qualification cycles can delay revenue conversion - Global supply chains expose production to logistics disruption - Input-cost and pricing pressure can affect customer adoption - Regulatory approval and food-safety standards are critical - IP and strain performance are central to product differentiation ## Accounting The company’s reported results are affected by judgement around goodwill, other intangible assets, and property, plant and equipment, since its value is heavily tied to acquired technology and internally developed scientific capabilities. Foreign exchange, tax, and hedge-related accounting can also move reported earnings because the group operates internationally and manages cross-border cash flows. Lease accounting and inventory valuation matter as well because manufacturing and supply-chain assets are significant in a global bioscience business. - **Goodwill and intangible impairment** — Could materially change reported earnings and equity - **Foreign exchange translation** — Can affect reported growth and profitability - **Inventory valuation** — Can affect gross margin and working capital - **Hedge accounting** — Can shift earnings between periods - Goodwill and intangibles require periodic impairment testing - Foreign exchange affects translation and operating results - Hedge accounting can smooth currency and commodity exposures - Inventory valuation matters for specialized biological products - Lease accounting affects reported liabilities and EBITDA-like measures --- *Last updated: 2026-10-24T15:03:40.489833+00:00*